Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?

Journal of Investigative Dermatology

Volumn 134, Issue 5, 2014, Pages 1468-1470

  Saint Jean, Mélanie ^a,b   Quéreux, Gaëlle ^a,b   Nguyen, Jean Michel ^c   Peuvrel, Lucie ^a,b   Brocard, Anabelle ^a,b   Vallée, Audrey ^a   Knol, Anne Chantal ^a,b   Khammari, Amir ^a,b   Denis, Marc G ^a   Dréno, Brigitte ^a,b  

^a HÔTEL DIEU   (France)

^b Team 12   (France)

^c CHU DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; VEMURAFENIB;

ALLELE; DNA SEQUENCE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LETTER; MELANOMA; METASTATIC MELANOMA; PATHOLOGIST; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; RETROSPECTIVE STUDY; TREATMENT RESPONSE; UNITED STATES; WILD TYPE; DRUG RESPONSE; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SKIN METASTASIS; VISCERAL METASTASIS;

HUMANS; INDOLES; MELANOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84900847127     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.378     Document Type: Letter

References (10)

1. Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516
2. Colombino M, Capone M, Lissia A et al. (2012) BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30:2522-2529
3. Davies H, Bignell GR, Cox C et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954
4. Flaherty KT, Puzanov I, Kim KB et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819
5. Gonzalez D, Fearfield L, Nathan P et al. (2013) BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel. Br J Dermatol 168:700-707
6. Jarry A, Masson D, Cassagnau E et al. (2004) Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Mol Cell Probes 18:349-352
7. Lade-Keller J, Romer KM, Guldberg P et al. (2013) Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas. J Mol Diagn 15:70-80
8. Lin J, Goto Y, Murata H et al. (2011) Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer 104:464-468
9. Schoenewolf NL, Dummer R, Mihic-Probst D et al. (2012) Detecting BRAF mutations in formalinfixed melanoma: experiences with two state-of-the-art techniques. Case Rep Oncol 5:280-289
10. Yancovitz M, Litterman A, Yoon J et al. (2012) Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One 7:e29336